206 related articles for article (PubMed ID: 16799655)
1. Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features.
Abd El-Wahed MM
J Egypt Natl Canc Inst; 2005 Sep; 17(3):173-83. PubMed ID: 16799655
[TBL] [Abstract][Full Text] [Related]
2. The paradoxical expression of maspin in ovarian carcinoma.
Sood AK; Fletcher MS; Gruman LM; Coffin JE; Jabbari S; Khalkhali-Ellis Z; Arbour N; Seftor EA; Hendrix MJ
Clin Cancer Res; 2002 Sep; 8(9):2924-32. PubMed ID: 12231537
[TBL] [Abstract][Full Text] [Related]
3. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E
Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598
[TBL] [Abstract][Full Text] [Related]
4. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
5. Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients.
Klasa-Mazurkiewicz D; Narkiewicz J; Milczek T; Lipińska B; Emerich J
Gynecol Oncol; 2009 Apr; 113(1):91-8. PubMed ID: 19193429
[TBL] [Abstract][Full Text] [Related]
6. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer.
Solomon LA; Munkarah AR; Schimp VL; Arabi MH; Morris RT; Nassar H; Ali-Fehmi R
Gynecol Oncol; 2006 Jun; 101(3):385-9. PubMed ID: 16443262
[TBL] [Abstract][Full Text] [Related]
7. [Expressions of Ki67, PCNA and mitotic index in ovarian epithelial tumors].
Wang S; Ma XY; Xia Y; Zhang LH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 41(4):575-80. PubMed ID: 20848772
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous expression of serine protease inhibitor maspin in ovarian cancer.
Bauerschlag DO; Habermann M; Weimer J; Meinhold-Heerlein I; Hilpert F; Weigel M; Bauer M; Mundhenke C; Jonat W; Maass N; Schem C
Anticancer Res; 2010 Jul; 30(7):2739-44. PubMed ID: 20683007
[TBL] [Abstract][Full Text] [Related]
9. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC
Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathologic features observation of ovarian transitional cell tumors].
Wang L; Dong Y; Li Q; Li H; Sun X; Zhou X; Li X
Zhonghua Bing Li Xue Za Zhi; 2015 Feb; 44(2):118-22. PubMed ID: 25916643
[TBL] [Abstract][Full Text] [Related]
11. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors.
Giurgea LN; Ungureanu C; Mihailovici MS
Rom J Morphol Embryol; 2012; 53(4):967-73. PubMed ID: 23303020
[TBL] [Abstract][Full Text] [Related]
12. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
13. Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.
Hasby EA
Tumour Biol; 2016 Apr; 37(4):4889-900. PubMed ID: 26526579
[TBL] [Abstract][Full Text] [Related]
14. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
; Secord AA; Lee PS; Darcy KM; Havrilesky LJ; Grace LA; Marks JR; Berchuck A
Gynecol Oncol; 2006 Jun; 101(3):390-7. PubMed ID: 16551475
[TBL] [Abstract][Full Text] [Related]
15. Expression of Sox2 in human ovarian epithelial carcinoma.
Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
J Cancer Res Clin Oncol; 2011 Jan; 137(1):131-7. PubMed ID: 20349085
[TBL] [Abstract][Full Text] [Related]
16. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications.
Logani S; Oliva E; Amin MB; Folpe AL; Cohen C; Young RH
Am J Surg Pathol; 2003 Nov; 27(11):1434-41. PubMed ID: 14576476
[TBL] [Abstract][Full Text] [Related]
17. Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer.
Xi C; Ren C; Hu A; Lin J; Yao Q; Wang Y; Gao Z; An X; Liu C
Gynecol Oncol; 2013 Dec; 131(3):764-71. PubMed ID: 23994105
[TBL] [Abstract][Full Text] [Related]
18. [Expression of maspin and its relation to tumor vascularization in epithelian ovarian cancer].
Ma Y; Peng ZL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Mar; 40(2):223-7. PubMed ID: 19462894
[TBL] [Abstract][Full Text] [Related]
19. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
20. Common epithelial tumors of the ovary: proliferating and of low malignant potential.
Ulbright TM; Roth LM
Semin Diagn Pathol; 1985 Feb; 2(1):2-15. PubMed ID: 2832916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
